Loading...

Dr. Lal PathLabs

NSEI:LALPATHLAB
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LALPATHLAB
NSEI
₹88B
Market Cap
  1. Home
  2. IN
  3. Healthcare
Company description

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. The last earnings update was 69 days ago. More info.


Add to Portfolio Compare Print
LALPATHLAB Share Price and Events
7 Day Returns
4%
NSEI:LALPATHLAB
1.6%
IN Healthcare
1.7%
IN Market
1 Year Returns
24.5%
NSEI:LALPATHLAB
-2.7%
IN Healthcare
0.1%
IN Market
LALPATHLAB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dr. Lal PathLabs (LALPATHLAB) 4% 1.4% 1.5% 24.5% 8.7% -
IN Healthcare 1.6% 4% -2.8% -2.7% -10.6% 46%
IN Market 1.7% 2.7% 5.8% 0.1% 41.6% 73.3%
1 Year Return vs Industry and Market
  • LALPATHLAB outperformed the Healthcare industry which returned -2.7% over the past year.
  • LALPATHLAB outperformed the Market in India which returned 0.1% over the past year.
Price Volatility
LALPATHLAB
Industry
5yr Volatility vs Market

Value

 Is Dr. Lal PathLabs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Dr. Lal PathLabs to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Dr. Lal PathLabs.

NSEI:LALPATHLAB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 15 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 14.5%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:LALPATHLAB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.72
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.715 (1 + (1- 35%) (0%))
0.809
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.809 * 8.6%)
14.51%

Discounted Cash Flow Calculation for NSEI:LALPATHLAB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Dr. Lal PathLabs is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:LALPATHLAB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 14.51%)
2019 1,770.50 Analyst x8 1,546.16
2020 2,095.33 Analyst x9 1,597.97
2021 2,637.88 Analyst x8 1,756.82
2022 3,271.00 Analyst x1 1,902.44
2023 3,668.00 Analyst x1 1,863.02
2024 4,170.00 Analyst x1 1,849.62
2025 4,637.58 Est @ 11.21% 1,796.37
2026 5,106.63 Est @ 10.11% 1,727.42
2027 5,583.84 Est @ 9.34% 1,649.51
2028 6,075.58 Est @ 8.81% 1,567.35
Present value of next 10 years cash flows ₹17,256.69
NSEI:LALPATHLAB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ₹6,075.58 × (1 + 7.55%) ÷ (14.51% – 7.55%)
₹93,887.93
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹93,887.93 ÷ (1 + 14.51%)10
₹24,220.80
NSEI:LALPATHLAB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹17,256.69 + ₹24,220.80
₹41,477.49
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹41,477.49 / 83.34
₹497.68
NSEI:LALPATHLAB Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NSEI:LALPATHLAB represents 0.99934x of BSE:539524
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99934x
Value per Share
(Listing Adjusted, INR)
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 497.68 x 0.99934
₹497.35
Value per share (INR) From above. ₹497.35
Current discount Discount to share price of ₹1,063.35
= -1 x (₹1,063.35 - ₹497.35) / ₹497.35
-113.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Dr. Lal PathLabs is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dr. Lal PathLabs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dr. Lal PathLabs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:LALPATHLAB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in INR ₹23.36
BSE:539524 Share Price ** BSE (2019-04-18) in INR ₹1064.05
India Healthcare Industry PE Ratio Median Figure of 23 Publicly-Listed Healthcare Companies 23.87x
India Market PE Ratio Median Figure of 2,735 Publicly-Listed Companies 16.29x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dr. Lal PathLabs.

NSEI:LALPATHLAB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:539524 Share Price ÷ EPS (both in INR)

= 1064.05 ÷ 23.36

45.55x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dr. Lal PathLabs is overvalued based on earnings compared to the IN Healthcare industry average.
  • Dr. Lal PathLabs is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does Dr. Lal PathLabs's expected growth come at a high price?
Raw Data
NSEI:LALPATHLAB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 45.55x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts
19.2%per year
Asia Healthcare Industry PEG Ratio Median Figure of 13 Publicly-Listed Healthcare Companies 1.76x
India Market PEG Ratio Median Figure of 584 Publicly-Listed Companies 1.33x

*Line of best fit is calculated by linear regression .

NSEI:LALPATHLAB PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 45.55x ÷ 19.2%

2.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dr. Lal PathLabs is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Dr. Lal PathLabs's assets?
Raw Data
NSEI:LALPATHLAB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in INR ₹106.12
BSE:539524 Share Price * BSE (2019-04-18) in INR ₹1064.05
India Healthcare Industry PB Ratio Median Figure of 33 Publicly-Listed Healthcare Companies 1.99x
India Market PB Ratio Median Figure of 3,626 Publicly-Listed Companies 1.12x
NSEI:LALPATHLAB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:539524 Share Price ÷ Book Value per Share (both in INR)

= 1064.05 ÷ 106.12

10.03x

* Primary Listing of Dr. Lal PathLabs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dr. Lal PathLabs is overvalued based on assets compared to the IN Healthcare industry average.
X
Value checks
We assess Dr. Lal PathLabs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Dr. Lal PathLabs has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Dr. Lal PathLabs expected to perform in the next 1 to 3 years based on estimates from 15 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dr. Lal PathLabs expected to grow at an attractive rate?
  • Dr. Lal PathLabs's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Dr. Lal PathLabs's earnings growth is expected to exceed the India market average.
  • Dr. Lal PathLabs's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
Raw Data
NSEI:LALPATHLAB Future Growth Rates Data Sources
Data Point Source Value (per year)
NSEI:LALPATHLAB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts 19.2%
NSEI:LALPATHLAB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts 13.1%
India Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 40.8%
India Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 12.6%
India Market Earnings Growth Rate Market Cap Weighted Average 18.7%
India Market Revenue Growth Rate Market Cap Weighted Average 11.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:LALPATHLAB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:LALPATHLAB Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 24,022 4,520 1
2023-03-31 20,980 4,018 1
2022-03-31 18,323 3,571 1
2021-03-31 16,304 2,918 2,918 14
2020-03-31 14,061 2,502 2,448 15
2019-03-31 12,133 2,121 2,022 15
NSEI:LALPATHLAB Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-12-31 11,691 1,923
2018-09-30 11,393 1,825
2018-06-30 10,999 1,761
2018-03-31 10,569 1,971 1,708
2017-12-31 10,100 1,617
2017-09-30 9,548 1,565
2017-06-30 9,389 1,586
2017-03-31 9,124 1,713 1,546
2016-12-31 8,902 1,576
2016-09-30 8,713 1,876
2016-06-30 8,249 1,413
2016-03-31 7,913 1,585 1,322

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Dr. Lal PathLabs's earnings are expected to grow by 19.2% yearly, however this is not considered high growth (20% yearly).
  • Dr. Lal PathLabs's revenue is expected to grow by 13.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:LALPATHLAB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below

All data from Dr. Lal PathLabs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:LALPATHLAB Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31
2021-03-31 35.09 40.00 30.30 12.00
2020-03-31 29.41 31.70 26.55 12.00
2019-03-31 24.31 26.20 22.47 12.00
NSEI:LALPATHLAB Past Financials Data
Date (Data in INR Millions) EPS *
2018-12-31 23.36
2018-09-30 22.20
2018-06-30 21.45
2018-03-31 20.85
2017-12-31 19.49
2017-09-30 18.88
2017-06-30 19.15
2017-03-31 19.02
2016-12-31 19.05
2016-09-30 20.34
2016-06-30 15.85
2016-03-31 16.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Dr. Lal PathLabs is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Dr. Lal PathLabs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dr. Lal PathLabs has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Dr. Lal PathLabs performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dr. Lal PathLabs's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dr. Lal PathLabs's year on year earnings growth rate has been positive over the past 5 years.
  • Dr. Lal PathLabs's 1-year earnings growth exceeds its 5-year average (18.9% vs 15.2%)
  • Dr. Lal PathLabs's earnings growth has exceeded the IN Healthcare industry average in the past year (18.9% vs -2.4%).
Earnings and Revenue History
Dr. Lal PathLabs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dr. Lal PathLabs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:LALPATHLAB Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 11,691.18 1,922.65 2,293.77
2018-09-30 11,393.18 1,824.65 2,237.77
2018-06-30 10,999.18 1,760.65 2,172.77
2018-03-31 10,569.18 1,707.65 2,101.77
2017-12-31 10,099.83 1,617.05 898.00
2017-09-30 9,547.83 1,565.05 808.00
2017-06-30 9,388.83 1,586.05 752.00
2017-03-31 9,123.83 1,545.88 1,693.70
2016-12-31 8,901.88 1,576.50 700.38
2016-09-30 8,713.08 1,875.90 675.88
2016-06-30 8,248.58 1,412.70 625.28
2016-03-31 7,913.18 1,321.90 580.28
2015-12-31 7,654.30 1,201.37 2,151.57 11.15
2015-03-31 6,595.90 907.67 497.25
2014-03-31 5,579.47 762.71 1,755.40 9.54
2013-03-31 4,516.61 521.28 1,443.59 11.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Dr. Lal PathLabs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Dr. Lal PathLabs used its assets more efficiently than the IN Healthcare industry average last year based on Return on Assets.
  • Dr. Lal PathLabs's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Dr. Lal PathLabs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dr. Lal PathLabs has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Dr. Lal PathLabs's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dr. Lal PathLabs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dr. Lal PathLabs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Dr. Lal PathLabs's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dr. Lal PathLabs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Dr. Lal PathLabs has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dr. Lal PathLabs Company Filings, last reported 3 months ago.

NSEI:LALPATHLAB Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 8,781.00 0.00 6,505.00
2018-09-30 8,781.00 0.00 6,505.00
2018-06-30 7,949.70 0.00 4,551.99
2018-03-31 7,949.70 0.00 4,551.99
2017-12-31 6,848.00 0.00 4,414.00
2017-09-30 6,848.00 0.00 4,414.00
2017-06-30 6,621.92 0.00 3,428.88
2017-03-31 5,979.57 0.00 3,397.16
2016-12-31 6,105.40 0.00 3,449.70
2016-09-30 6,105.40 0.00 3,449.70
2016-06-30 5,102.38 0.00 2,939.68
2016-03-31 5,102.38 0.00 2,742.74
2015-12-31
2015-03-31 3,433.76 0.00 1,861.02
2014-03-31 2,333.33 16.03 1,142.52
2013-03-31 1,636.73 12.28 762.34
  • Dr. Lal PathLabs has no debt.
  • Dr. Lal PathLabs has no debt compared to 5 years ago when it was 0.7%.
  • Dr. Lal PathLabs has no debt, it does not need to be covered by operating cash flow.
  • Dr. Lal PathLabs has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Dr. Lal PathLabs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dr. Lal PathLabs has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Dr. Lal PathLabs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.52%
Current annual income from Dr. Lal PathLabs dividends. Estimated to be 0.48% next year.
If you bought ₹2,000 of Dr. Lal PathLabs shares you are expected to receive ₹10 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Dr. Lal PathLabs's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.49%).
  • Dr. Lal PathLabs's dividend is below the markets top 25% of dividend payers in India (1.92%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:LALPATHLAB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
India Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.7%
India Market Average Dividend Yield Market Cap Weighted Average of 1399 Stocks 1.3%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 1.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:LALPATHLAB Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31
2021-03-31 5.35 10.00
2020-03-31 4.81 10.00
2019-03-31 4.42 9.00
NSEI:LALPATHLAB Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2018-11-29 5.500 0.548
2018-05-14 4.500 0.490
2017-11-09 3.200 0.364
2017-05-12 3.400 0.413
2017-02-02 2.600 0.268
2016-07-29 2.450 0.227
2016-05-30 2.450 0.262
2016-02-15 0.000 0.000
2015-12-23 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Dr. Lal PathLabs has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Dr. Lal PathLabs only paid a dividend in the past 3 years.
Current Payout to shareholders
What portion of Dr. Lal PathLabs's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (4.2x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (6.4x coverage).
X
Income/ dividend checks
We assess Dr. Lal PathLabs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dr. Lal PathLabs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dr. Lal PathLabs has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Dr. Lal PathLabs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Om Manchanda
COMPENSATION ₹29,720,187
AGE 53
TENURE AS CEO 11 years
CEO Bio

Dr. Om Prakash Manchanda, also known as Om, has been the Chief Executive Officer of Dr. Lal PathLabs Pvt. Ltd. since April 01, 2008 and has been its Whole Time Director since February 01, 2011. He has a diverse experience of over 24 years across sales, marketing and general management functions in business sectors such as FMCG, agri-biotech products, consumer healthcare and medical diagnostics. Dr. Manchanda served as the Chief Operating Officer of Dr. Lal PathLabs Pvt. Ltd. He joined Dr Lal PathLabs in 2005. He led the International & Innovation group of the Consumer Healthcare Division at Ranbaxy. He was part of the senior management team responsible for launching Ranbaxy’s foray into consumer healthcare. Prior to Ranbaxy, he worked at Monsanto as the head of Sales and Marketing, where his team successfully launched the company’s first ever biotech product Bt-Cotton. He served at Hindustan Unilever for about 10 years. He received in-depth exposure in consumer product sales, distribution and marketing. He cherishes the memory of how at Unilever, as the Senior Brand Manager - Innovation, he had led the designing and launching of a tea-based beverage at HLL, which won Unilever's Global Innovation Award. Dr. Manchanda considers that award special among the several awards he had received at Unilever. He has been an Independent Director at Prataap Snacks Limited since July 05, 2016. He is an avid reader of management books with his favorite authors being Steven Covey, Jack Welch, Peter M Senge and John Philip Jones. He has an MBA from the Indian Institute of Management, Ahmadabad. Dr. Manchanda is also a Doctor in Veterinary Sciences from HAU, Hisar. Dr. Manchanda holds a bachelor's degree in veterinary science and animal husbandry Agricultural University from the Haryana Agricultural University and a post graduate diploma in management (agriculture) from the Indian Institute of Management, Ahmadabad.

CEO Compensation
  • Om's compensation has been consistent with company performance over the past year.
  • Om's remuneration is about average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Dr. Lal PathLabs management team in years:

4.2
Average Tenure
53
Average Age
  • The tenure for the Dr. Lal PathLabs management team is about average.
Management Team

Arvind Lal

TITLE
Chairman & MD
COMPENSATION
₹22M
AGE
69

Om Manchanda

TITLE
CEO & Whole Time Director
COMPENSATION
₹30M
AGE
53
TENURE
11 yrs

Rajat Kalra

TITLE
Legal Head
COMPENSATION
₹3M
AGE
41
TENURE
3.8 yrs

Vandana Lal

TITLE
Whole-Time Director
COMPENSATION
₹18M
AGE
61

C. A. Ved Goel

TITLE
Chief Financial Officer
TENURE
0.7 yrs

Bharath Uppiliappan

TITLE
Chief Operating Officer
TENURE
1.3 yrs

Munender Soperna

TITLE
Chief Information Officer
TENURE
4.8 yrs

Manoj Sahay

TITLE
Chief Marketing & Strategy Officer
TENURE
1.8 yrs

Manoj Garg

TITLE
Chief Human Resources Officer
AGE
49
TENURE
4.5 yrs

Shankha Banerjee

TITLE
Chief Growth Officer
TENURE
4.7 yrs
Board of Directors Tenure

Average tenure and age of the Dr. Lal PathLabs board of directors in years:

3.7
Average Tenure
59.5
Average Age
  • The tenure for the Dr. Lal PathLabs board of directors is about average.
Board of Directors

Om Manchanda

TITLE
CEO & Whole Time Director
COMPENSATION
₹30M
AGE
53
TENURE
8.2 yrs

Vandana Lal

TITLE
Whole-Time Director
COMPENSATION
₹18M
AGE
61
TENURE
24.2 yrs

Sunil Varma

TITLE
Independent Non-Executive Director
COMPENSATION
₹2M
AGE
74
TENURE
3.7 yrs

Arvind Lal

TITLE
Chairman & MD
COMPENSATION
₹22M
AGE
69

Saurabh Srivastava

TITLE
Independent Non-Executive Director
COMPENSATION
₹2M
AGE
71
TENURE
3.7 yrs

Rahul Sharma

TITLE
Non Executive Director
AGE
58
TENURE
13.8 yrs

Anoop Singh

TITLE
Independent Non-Executive Director
COMPENSATION
₹1M
AGE
47
TENURE
3.7 yrs

Harneet Chandhoke

TITLE
Independent Non-Executive Director
COMPENSATION
₹2M
AGE
52
TENURE
3.7 yrs

Somya Satsangi

TITLE
Independents Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • Dr. Lal PathLabs insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
27. Mar 19 Sell Bharath Uppiliappan Individual 22. Mar 19 26. Mar 19 -1,250 ₹1,075.40 ₹-1,344,252
11. Mar 19 Sell Reena Nakra Individual 06. Mar 19 06. Mar 19 -1,000 ₹1,018.98 ₹-1,018,977
22. Feb 19 Sell Manoj Garg Individual 15. Feb 19 21. Feb 19 -1,032 ₹1,034.60 ₹-1,067,704
21. Feb 19 Sell Neelum Tripathi Individual 19. Feb 19 19. Feb 19 -1,000 ₹1,024.92 ₹-1,024,924
15. Feb 19 Sell Munender Soperna Individual 11. Feb 19 13. Feb 19 -2,975 ₹1,040.88 ₹-3,096,611
15. Feb 19 Buy Munender Soperna Individual 13. Feb 19 13. Feb 19 50 ₹1,026.85 ₹51,342
05. Dec 18 Sell Neelum Tripathi Individual 03. Dec 18 03. Dec 18 -2,000 ₹878.78 ₹-1,757,551
24. Sep 18 Sell Shankha Banerjee Individual 29. Aug 18 29. Aug 18 -500 ₹1,114.00 ₹-557,000
31. Aug 18 Sell Neelum Tripathi Individual 29. Aug 18 29. Aug 18 -1,500 ₹1,100.91 ₹-1,651,372
29. Aug 18 Sell Shankha Banerjee Individual 24. Aug 18 27. Aug 18 -3,000 ₹1,046.77 ₹-3,140,308
29. Aug 18 Sell Manoj Garg Individual 27. Aug 18 27. Aug 18 -1,500 ₹1,060.00 ₹-1,590,000
23. Aug 18 Sell Bharath Uppiliappan Individual 17. Aug 18 17. Aug 18 -200 ₹1,004.00 ₹-200,800
23. Aug 18 Sell Shankha Banerjee Individual 17. Aug 18 21. Aug 18 -1,500 ₹1,025.33 ₹-1,538,000
04. Jul 18 Sell Manoj Garg Individual 25. Jun 18 29. Jun 18 -1,500 ₹957.97 ₹-1,436,950
02. Jul 18 Sell Shankha Banerjee Individual 28. Jun 18 29. Jun 18 -1,500 ₹940.00 ₹-1,410,000
29. Jun 18 Sell Neelum Tripathi Individual 28. Jun 18 28. Jun 18 -2,000 ₹930.01 ₹-1,860,022
25. Jun 18 Sell Dilip Bidani Individual 21. May 18 22. Jun 18 -3,000 ₹910.33 ₹-2,731,000
20. Jun 18 Sell Om Manchanda Individual 18. Jun 18 18. Jun 18 -100,000 ₹863.01 ₹-86,300,716
31. May 18 Sell Om Manchanda Individual 29. May 18 31. May 18 -28,070 ₹866.94 ₹-24,335,071
18. May 18 Buy C. A. Ved Goel Individual 14. May 18 14. May 18 8,866 ₹110.80 ₹982,353
X
Management checks
We assess Dr. Lal PathLabs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dr. Lal PathLabs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) 0.5% Dividend Yield Looks Pretty Interesting

Unfortunately, one common occurrence with dividend companies is for investors to be enticed in by the seemingly attractive yield, and lose money when the company has to cut its dividend payments.. … Many of the best dividend stocks typically start out paying a low yield, so we wouldn't automatically cut it from our list of prospects.! … Before you buy any stock for its dividend however, you should always remember Warren Buffett's two rules: 1) Don't lose money, and 2) Remember rule #1

Simply Wall St -

Is Dr. Lal PathLabs Limited’s (NSE:LALPATHLAB) 29% ROCE Any Good?

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … Return On Capital Employed (ROCE): What is it? … ROCE measures the 'return' (pre-tax profit) a company generates from capital employed in its business.

Simply Wall St -

Should You Be Pleased About The CEO Pay At Dr. Lal PathLabs Limited's (NSE:LALPATHLAB)

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Om Manchanda's Compensation Compare With Similar Sized Companies. … While we always look at total compensation first, we note that the salary component is less, at ₹28m

Simply Wall St -

Should You Be Tempted To Sell Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Because Of Its P/E Ratio?

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … That is equivalent to an earnings yield of about 2.2%. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Does Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) 19% Earnings Growth Make It An Outperformer?

For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. … Did LALPATHLAB's recent earnings growth beat the long-term trend and the industry. … LALPATHLAB's trailing twelve-month earnings (from 31 December 2018) of ₹1.9b has.

Simply Wall St -

How Much Are Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Insiders Taking Off The Table?

It's quite normal to see company insiders, such as board members, trading in company stock, from time to time. … In the last twelve months, the biggest single sale by an insider was when CEO & Whole Time Director Om Manchanda sold ₹86m worth of shares at a price of ₹863 per share. … As a general rule we consider it to be discouraging when insiders are selling below the current price

Simply Wall St -

A Holistic Look At Dr. Lal PathLabs Limited (NSE:LALPATHLAB)

Help shape the future of investing tools and you could win a $250 gift card! … Building up an investment case requires looking at a stock holistically. … Lal PathLabs Limited (NSE:LALPATHLAB) due to its excellent fundamentals in more than one area.

Simply Wall St -

Do Directors Own Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Shares?

Generally speaking, as a company grows, institutions will increase their ownership. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Is Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Spending Too Much Money?

Lal PathLabs’s cash flow health and the risk-return concept based on the stock’s cash flow yield, using the most recent financial data. … This will help you think about the company from a cash perspective, which is a crucial factor to investing. … Free cash flow (FCF) is the amount of cash Dr

Simply Wall St -

Is Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Excessively Paying Its CEO?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … Lal PathLabs Limited has a market capitalization of ₹80b, and pays its CEO total annual compensation worth ₹30m. … We looked at a group of companies with market capitalizations from ₹28b to ₹112b, and the median CEO compensation was ₹24m.

Simply Wall St -

Company Info

Description

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company offers a range of diagnostic and related healthcare tests and services for use in core testing and patient diagnosis, as well as in the prevention, monitoring, and treatment of disease and other health conditions. Its customers include individual patients, hospitals, other healthcare providers, and corporate customers. As of May 14, 2018, the company owned and operated a National Reference Laboratory in New Delhi, as well as 191 other clinical laboratories, 2,153 patient service centers, and approximately 5,624 pickup points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurgaon, India.

Details
Name: Dr. Lal PathLabs Limited
LALPATHLAB
Exchange: NSEI
Founded: 1949
₹87,683,707,881
83,341,610
Website: http://www.lalpathlabs.com
Address: Dr. Lal PathLabs Limited
Tower B, SAS Tower,
12th Floor,
Gurgaon,
Haryana, 122001,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 539524 Equity Shares Mumbai Stock Exchange IN INR 23. Dec 2015
NSEI LALPATHLAB Equity Shares National Stock Exchange of India IN INR 23. Dec 2015
Number of employees
Current staff
Staff numbers
4,316
Dr. Lal PathLabs employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 13:03
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/02/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.